China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited (CSWYY) Revenue
Annual & quarterly revenue history · segment & region breakdown
CSWYY · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsChina Shineway Pharmaceutical Group Limited trailing twelve-month (TTM) revenue is $6.91B, a decrease of 19.27% year-over-year from $3.05B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $3.05B | -$0.73B | -19.27% |
| 2024-12-31 | $3.78B | -$0.74B | -16.35% |
| 2023-12-31 | $4.52B | +$0.50B | +12.35% |
| 2022-12-31 | $4.02B | +$0.84B | +26.34% |
| 2021-12-31 | $3.18B | +$0.53B | +19.81% |
| 2020-12-31 | $2.66B | -$0.05B | -1.86% |
| 2019-12-31 | $2.71B | +$0.14B | +5.28% |
| 2018-12-31 | $2.57B | +$0.65B | +33.89% |
| 2017-12-31 | $1.92B | -$0.17B | -7.94% |
| 2016-12-31 | $2.09B | +$0.03B | +1.47% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income China Shineway Pharmaceutical Group Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
China Shineway Pharmaceutical Group Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CNY.
Data sourced from China Shineway Pharmaceutical Group Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CSWYY revenue · 4 questionsCSWYY's trailing twelve-month (TTM) revenue is $6.91B. That is a decrease of 19.27% year-over-year from $3.05B in FY2025.
▸ Source: FMP · China Shineway Pharmaceutical Group Limited SEC filings · GAAP · China Shineway Pharmaceutical Group Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026